FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) has started the development of "Fracture Screening AI Program", which is FRONTEO's second AI medical device pipeline.

　This system utilizes the technology of the natural language processing AI engine "Concept Encoder (trademark: concept encoder, reading: concept encoder)" originally developed by FRONTEO, and breaks in the hospital from the medical information written in the electronic medical record of the inpatient. It screens for potential patients.Fractures are a significant risk not only to bedridden and dementia progression, but also to death, especially in the elderly.As the aging society progresses, fracture prevention for the elderly is one of the important social issues, and FRONTEO has started the development of a fracture screening AI program to contribute to the solution.

　FRONTEO obtained a license for the first-class medical device manufacturing and sales business from Tokyo in January this year (license number: 1B13X1), and in-house processes from medical device technology development, product development, clinical development, manufacturing, and sales. We have built a system that can be done with.Currently, aiming to obtain regulatory approval for the world's first language-based AI medical device, following the "Conversational Dementia Diagnosis Support AI System" that started clinical trials in April and the "Fracture Screening AI Program" that started this time. We will continue to develop AI medical devices and contribute to the promotion of medical safety, improvement of quality, and improvement of patient QOL.

■ About the first-class medical device manufacturing and sales business license
In Japan, the manufacture and sale of pharmaceuticals and medical devices is regulated by the "Act on Securing Quality, Effectiveness and Safety of Pharmaceuticals and Medical Devices" (commonly known as the Pharmaceutical Machinery Law), and the Ministry of Health, Labor and Welfare and prefectures It is necessary to obtain the permission and approval of.The medical device manufacturing and sales business is a business format that ships and markets medical devices and is responsible for the effectiveness, safety, and quality of the products.We carry out safety and quality control when actually using medical devices, as well as collecting, analyzing, and responding to the necessary information, including applications and notifications for approval of medical devices.Medical devices are classified into classes I to IV according to the degree of risk given to users, and the types of business licenses required differ depending on this class.The first-class medical device manufacturing and sales business is a qualification that enables the handling of all classes of medical devices.

■ About conversational dementia diagnosis support system　URL: https://lifescience.fronteo.com/aidevice/dementia/
The conversational dementia diagnosis support system (AI medical device) uses FRONTEO's original natural language analysis AI "Concept Encoder (trademark: conceptencoder, reading: concept encoder)" for 5 to 10 minutes between the patient and the doctor. It is a system that can screen for cognitive dysfunction from daily conversation.We believe that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which is facing a super-aging society. I will. FRONTEO entered into a business alliance agreement with Kyowa Pharmaceutical Industry Co., Ltd., which aims to become a CNS (central nervous system) total solution company, in June 2020, aiming for early commercialization and early market penetration in the medical field.Patent registration number: Patent No. 6

■ About Concept Encoder　URL:https://lifescience.fronteo.com/technology/conceptencoder/

"Concept Encoder (registered trademark: concept encoder, reading: concept encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■FRONTEOabout　URL:https://www.fronteo.com/

FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, with a focus on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and OSINT from 8, and created by using AI to "turn text data into knowledge". We contribute to solving various corporate issues such as drug support, dementia diagnosis support, financial, human resources, and sales support. Listed on TSE Mothers on June 2014, 2007. January 6 Obtained a first-class medical device manufacturing and sales license (permit number: 26B2021X1).The capital is 13 thousand yen (as of March 1, 10350).

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.